Navigation Links
Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
Date:10/17/2007

onically debilitating condition that affects no more than five in 10,000 persons in the European Union.

About Picoplatin

Picoplatin is a new generation platinum chemotherapy agent. It was designed to overcome platinum resistance and to prolong the time to relapse after chemotherapy in the treatment of solid tumors, and to have an improved safety profile compared with existing platinum-based chemotherapeutics. Poniard received orphan drug designation from the FDA in November 2005 for picoplatin for the treatment of SCLC.

In addition to the SPEAR trial of intravenous picoplatin in SCLC, Poniard is also evaluating intravenous picoplatin in an ongoing Phase 1 clinical trial as a first-line treatment for metastatic colorectal cancer and in an ongoing Phase 2 trial in combination with docetaxel (Taxotere(R)) and prednisone in patients with metastatic hormone-refractory prostate cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.

About Small Cell Lung Cancer

SCLC is the most aggressive and deadly form of lung cancer and accounts for approximately 20 percent of all lung cancer cases. The current two-year survival rate for patients with extensive SCLC is less than 10 percent with current management options. The estimated incidence of lung cancer in the United States in 2006 was 174,500, according to the National Cancer Institute. The estimated incidence in Europe in 2006 was 386,300, according to the International Agency for Research on Cancer.

SCLC is currently treated with platinum therapies, but many patients do not respond, and if they do respond, they typically relapse within a short time after treatment. There is currently no FDA-approved therapy and no consistent and effective therapy for SCLC patients who have platinum-resistant or -refractory disease after treatment failure with first-line combination therapy with either cisplatin or carboplatin. No new drugs have been approved by the FDA for th
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... White papers by Clinovo ... eClinical technologies, have been published by leading pharmaceutical publications ... long line of white papers by Clinovo to have ... Leader, Pharmaceutical Online, and OpenHealthNews. , At the request ... CTO Marc Desgrousilliers, 'The Five Essentials of Cloud ...
(Date:7/29/2014)... July 29, 2014 ... (LBS) zur Erfassung biologischer Daten in Verbindung ... und patentiert. Das LBS nimmt gleichzeitig mehrere ... des Patienten und sucht erhöhte biologische Aktivitäten ... Potenzial, die Entdeckung und Entwicklung neuer Medikamente ...
(Date:7/28/2014)... SAN DIEGO , July 28, 2014 ... algae cultivation technologies, today announced the appointment of biotechnology ... member of the board of directors. Levine replaces Cynthia ... effective immediately. She will remain chairman of the company,s ... leadership on Sapphire Energy,s mission to deliver commercial scale ...
(Date:7/28/2014)... 2014 “2014 Deep Research ... is a professional and in-depth research report ... report introduces Lubricant basic information, including Lubricant ... and industry overview. This research covers the ... as well as global industry analysis covering ...
Breaking Biology Technology:Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 4Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 4
... completed phase of the new Children,s,Hospital campus, PITTSBURGH, ... opened its new 10-story, state-of-the-art John G. Rangos,Sr. Research ... new,premier pediatric campus., With more than 300,000 square ... hub of pediatric health research for the region. The ...
... October 29, Rosetta Genomics Ltd. (Nasdaq: ROSG ), ... today its,management will present at Oppenheimer 19th Annual ... Waldorf-Astoria Hotel in New York,City., About MicroRNA, ... small,RNAs that act as master regulators and have ...
... at ImClone Brings Substantial,Oncology Drug Development Expertise, ... ("Senesco" or the "Company") (NYSE Alternext US: SNT),announced ... 55 to its board,of directors. Senesco,s board of ... are independent., (Photo: http://www.newscom.com/cgi-bin/prnh/20081029/NY42202 ), ...
Cached Biology Technology:Opening Dedication of the New John G. Rangos Sr. Research Center at the New Children's Hospital of Pittsburgh of UPMC Campus in Lawrenceville 2Opening Dedication of the New John G. Rangos Sr. Research Center at the New Children's Hospital of Pittsburgh of UPMC Campus in Lawrenceville 3Rosetta Genomics to Present at Oppenheimer's 19th Annual Healthcare Conference 2Rosetta Genomics to Present at Oppenheimer's 19th Annual Healthcare Conference 3Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors 2Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors 3
(Date:7/28/2014)... An international team of researchers led by the University ... rice. , The genetic information will enhance scientists, and ... as well as enable the development of new rice ... environmental stressors to help solve global hunger challenges. , ... Oryza glaberrima ) and evidence for independent domestication," was ...
(Date:7/28/2014)... Reactions among minerals and organic compounds in hydrothermal environments ... they provide energy for the deep biosphere, and may ... little is known about how minerals influence organic reactions. ... have demonstrated how a common mineral acts as a ... need for toxic solvents or expensive reagents. , At ...
(Date:7/28/2014)... mechanism in part of the brain that is key to ... type 1 and type 2 diabetes. The findings are published ... National Academies of Sciences . , "We,ve discovered that ... the hypothalamus known as the ventromedial nucleus sets a ... the blood," said lead author Sabrina Diano, professor in the ...
Breaking Biology News(10 mins):Generating a genome to feed the world: UA-led team sequences African rice 2Generating a genome to feed the world: UA-led team sequences African rice 3Generating a genome to feed the world: UA-led team sequences African rice 4Mineral magic? Common mineral capable of making and breaking bonds 2Mineral magic? Common mineral capable of making and breaking bonds 3Glucose 'control switch' in the brain key to both types of diabetes 2
... are primary producers of ammonia in Houston,s atmosphere, and cars ... according to a new study by researchers at Rice University ... air quality draws minimal oversight from the Environmental Protection Agency ... it means to life in and around the metropolis. ...
... N.Y. DNA and protein sequencing have forever ... of these complex biomolecules has revolutionized drug development, ... evolution and development. But, one major molecule in ... biopolymers. Today, for the first time ...
... A tiny piece of a critical receptor that fuels the ... discovered by University at Buffalo scientists as a promising new ... on the NMDA (N-methyl-D-aspartate) receptor is being published online Oct. ... time that this site has been shown to be useful ...
Cached Biology News:Ammonia gets overdue overview 2Ammonia gets overdue overview 3Uncharted territory: Scientists sequence the first carbohydrate biopolymer 2Uncharted territory: Scientists sequence the first carbohydrate biopolymer 3New drug target for Alzheimer's, stroke is discovered by University at Buffalo scientists 2
Polyclonal antiserum raised against conjugated L-isoleucine. Available as antiserum. Amino Acid Antibodies...
Rabbit polyclonal to FOXJ2 ( Abpromise for all tested applications). entrezGeneID: 55810 SwissProtID: Q9P0K8...
Rabbit polyclonal to Oct2, prediluted ( Abpromise for all tested applications). entrezGeneID: 5452 SwissProtID: P09086...
Macrophage-stimulating protein receptor...
Biology Products: